PDL BioPharma — H.C. Wainwright & Co. Global Life Sciences Conference 2018
38 slides from PDL BioPharma's conference presentation, Apr 10, 2018

Slide 1: H.C. Wainwright Global Life Sciences Conference
PDL H.C. Wainwright & Co. Global Life Sciences Conference April 9-10, 2018

Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements, including PDL’s expectations with respect to its future royalty revenues, expenses, net income, and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actu

Slide 3: PDL at a Glance
PDL at a Glance PDL BioPharma seeks to provide a significant return for its shareholders by i and managing a portfolio of companies, products, royalty agreements and ies in the biotech, pharmaceutical and medical device industries. CURRENT EQUITY INVESTMENTS: Q Noden Pharma DAC, an Irish domiciled s

Slide 4: PDL Future: Focus on Growth Opportunities
PDL Future: Focus on Growth Opportunities Q Diversification via acquisition of additional pharma products and companies with a focus on under commercialized products. Specialty Pharma Q Noden expansion, commercializing products in U.S. and in key markets in the rest of world. Q Use proceeds from com

Slide 5: Key Information and Facts
Key Information and Facts Ticker PDLI (NASDAQ) Location Incline Village, Nevada Share Price $2.91 as of 04/02/2018 Book Value as of 12/31/2017 $5.54 per share Current Deployed on Royalty Investments $396 million Current Deployed on Debt Investments $20 million $1 Billion Deployed Current Deployed on

Slide 6: Building Value Through Investments
Building Value Through Investments PD SSSEEEENNNNCCLOR ER RTCA PRESSRGUSRESSRGUSREUSRENS RSASRSHSHSASRSASHSASHSAS, book value per share eased to $5.54 ending December 31, 2017 PDL's Book Value Per Share Does not include asset value of royalties from Queen et al patents.

Slide 7: Experienced Leadership
Experienced Leadership Management John McLaughlin Chief Executive Officer Dominique Monnet President Christopher Stone VP, General Counsel & Secretary Peter Garcia VP & Chief Financial Officer Steffen Pietzke VP, Finance & Chief Accounting Officer Nathan Kryszak Deputy General Counsel & Assistant Se

Slide 8: Recent Developments
PDL Recent Developments

Slide 9: PDL Share Repurchase Programs
PDL Share Repurchase Programs a Previous Program = In March 2017, PDL’s board authorized the repurchase of PDL common stock having an aggregate value of up to $30 million through March 2018. = Total repurchased under this program over 4 months was approximately 13.3 million shares at an average pric

Slide 10: Termination of Proposal to Acquire Neos
10 Termination of Proposal to Acquire Neos a In late 2017, PDL made public its proposal to acquire all of Neos’ shares for $10.25 per share. Q On February 20, 2018, PDL announced it was terminating its pursuit of acquiring Neos and does not plan to make any further proposals. a PDL liquidated its st

Slide 11: Noden Pharma
PDL NODEN y PHARMA

Slide 12: Noden Current Product Portfolio
Noden Current Product Portfolio Therapeutic & Geographic Area Olgas Ofesmasc: Hypertension - U.S. Step ey a ccc Hypertension - Rest of World = =

Slide 13: Current Noden Products
Current Noden Products United States a Tekturna® - aliskiren is a direct renin inhibitor for the treatment of hypertension that reduces plasma renin by inhibiting the conversion of angiotensinogen to angiotensin I. = Not for use with ACEls or ARBs in patients with diabetes or renal impairment and pr

Slide 14: Tekturna Market: Hypertension
Tekturna Market: Hypertension a Chronic condition with serious long-term cardiovascular implications which affects about 29% of the U.S. adult population. «, = 78 million in U.S. alone. a Majority of hypertension diagnosis and management occurs in primary care setting (PCP) with rare referrals when

Slide 15: Tekturna Products Labeling
Tekturna Products Labeling For full prescribing information for Tekturna and Tekturna HCT, please visit: www.tekturna.com. @. . (@ Oddities O Baumann 150 mg/t2:mg + 150 mg/26 mg + 300 mg/t2.5 mg » 300 mg/28 mg PDL

Slide 16: Tekturna: Safety Profile
Tekturna: Safety Profile Q Safety data in more than 6,460 patients, including 1,740 treated for longer than 6 months and more than 1,250 treated for longer than 1 year. Q Discontinuation of therapy due to clinical adverse event occurred in 2.2% of Tekturna treated patients compared to 3.5% of placeb

Slide 17: Tekturna: Safety Profile
v7 Tekturna: Safety Profile Placebo-Controlled Trials Tekturna () Adverse Event Selected AE’s in Patients with Type 2 Kidney Disease, Diabetes and Chro' CV Disease, or Both Edema 04 05 Diarrhea oS 42 Cough 14 06 Rash 40 03 Elevated Uric Acid 04 0.4 Gout 02 04 Renal Stones 02 0.0 Adverse Event Renal

Slide 18: Noden Pharma Entities
48 Noden Pharma Entities a Noden DAC = Domiciled in Ireland. = Expected to be a tax efficient structure. = Responsible for development and commercialization activities worldwide. = Responsible for bulk tablet manufacture worldwide and fill-and-finish ex-US. a Noden USA = Domiciled in Delaware. = Res

Slide 19: Product Transition from Novartis
Product Transition from Novartis Commercialization a US = Noden USA assumed commercialization responsibilities on October 5, 2016. =» Noden USA fielded a dedicated contract sales force of ~40 reps and 4 district managers in late February 2017 — the first promotional effort in 4 years. Increased dedi

Slide 20: Tekturna & Tekturna HCT Revenue
Tekturna & Tekturna HCT ly Revenu $in millions $9.00 $8,000; $7,445 $7.464 $7.193, 9783 6 aaa $6.943 $7.000 $6442 $6.565 $6.491 $6.474 $5.773 $5,910 $5.847 $6.000 35.488 $5,000 $4,000 $3,000 $2.000 $1,000 Pe Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 F

Slide 21: Tekturna & Tekturna HCT Prescriptions
Tekturna & Tekturna HCT Prescriptions Tekturna Prescription Data - All Strengths 3500 1500 See RS ieee 1000 Source: IMS Xponent weekly data PDL

Slide 22: Executing Targeted Patient-Type Strategy
Executing Targeted Patient-Type Strategy ACE/ ARB Intolerant: SWITCH CCB Notat Goal: ADD

Slide 23: Noden Team
Noden Team Q Chief Executive Officer = Alan Markey ° prywousy Managing Director of Baxter Healthcare Limited (Ireland), Assistant VP for Enbrel - Q Head of Sales and Marketing US * Michael McCann o Previously head of US Cardiovascular at Sanofi Genzyme, VP of Global Strategic Marketing for Cardiovas

Slide 24: Novartis/Tekturna Deal
24 Novartis/Tekturna Deal a Total Tekturna Potential Purchase Price » Up to $334 million. a Closing Payments = $110 million paid to Novartis in July 2016. a First Anniversary = $89 million paid to Novartis in July 2017. a Milestones » Up to $95 million based on sales levels and generic competition.

Slide 25: Tekturna Intellectual Property
Tekturna Intellectual Property Tekturna is protected by multiple patents covering composition of matter, pharmaceutical formulation and methods of manufacture. Q United States + Composition of matter protection to 2018 for Tekturna; listed in the Orange Book; possible extension for 6 months with suc

Slide 26: LENSAR
PDL (CATARACT LASER WITH AUGMENTED REALITY

Slide 27: LENSAR
| LENSAR Q LENSAR, Inc. is a leading global developer and manufacturer of Femtosecond Cataract Lasers (FLS) in the growing cataract surgery market. Q Cataract surgery is the highest volume surgical procedure globally. + Market penetration of FLS approx. 7% of total proceduresin U.S. while < 2% OUS.

Slide 28: LENSAR Highlights
28 LENSAR Highlights Leading Technology Platform Positioned For Growth Cataract surgery is the highest volume surgical procedure performed worldwide with over 24.9 million surgeries estimated to be performed in 2016. Integration of preoperative diagnostics into the cataract refractive suite driving

Slide 29: Investments Overview
PDL Investments Overview

Slide 30: Royalty & Debt Investments
16 Royalty & Debt Investments aaa) | aa aeiaauas | [ Tesnoremms a er eho danuant | | Sk Depomed | | | LENSAR purata | | OaroGen | | givens as ~ DURATA : s140n 00 21000000 scoo0npo0 s70.0 00 s20g00000 sssoog00 sceemeee | | Seeeten aes reboots een toe Converted to ety 022017 ee ee Tovatirnaciay) [Sede

Slide 31: Royalty Acquisitions — $496MM Invested
Royalty Acquisitions — $496MM Invested Glumetza 3,€Pevomed YYVALEANT indefinite Sens. 6/2018 Dini B 5/2026 ~ $240.5M — $308.5M_~ Janssen DT 9/2023 bois Yop, 12/2026 | Ingle EL a Payoff $100.0M_ — $120.0 (3) 7 . 4/2022 5.6M 8.2M felguste es ae Ed SANOFI GENZYME J $6 $ ZALVISO” =e os 1/2032 $65.0M $0.

Slide 32: Concluded Investment Track Record
Concluded Investment Track Record ($ in Millions) Transaction Cash 1x Cash | Cash Return Transaction Maturity Total © Amount Received Return (Money _Pre-Taxed Date Committed Invested byPDL (Years) __ Multiple) IRR% _ RSS ateor ene: b AxoGen Oct-2012 Nov-2014 20.8 26.4 40.0 | Durata Oct-2013 Nov-2014

Slide 33: Financials
PDL Financials

Slide 34: Fourth Quarter 2017 Financials
Fourth Quarter 2017 Financials ‘Three Months Ended ‘Twelve Months Ended December 31, December 31, (In thousands, except per share amounts) 2017 2016 2017 2016 Royalties from Queen et al. patents $4531 _$ 15,513. _$ 36,415 _$ 166,158 Royalty rights - change in fair value 30,103 28,068 162,327 16,196

Slide 35: Strong Balance Sheet
Strong Balance Sheet ($in millions) Cash, cash equivalents and short-term investments $532! Total Assets $1,243 Debt: 4.00% Convertible Debt- due 2/2018 ($9.17 conversion p/s) 126" 2.75% Convertible Debt - due 12/2021 ($3.81 conversion p/s)? 150 Total Debt (principal outstanding) $276 The 4.00% Conv

Slide 36: Valuing the Balance Sheet
Valuing the Balance Sheet $1,400 $1,200 $1,000 $800 $600 $400 $200 so Assets in millions ‘@Cash/inv. m Depomed ‘= U-Michigan m Other = Noden ma Wellstat sm AcelRx wm CareView mlensar Selected Component Cash Debt Net Cash Royalty Rights Noden & Lensar Book Value Notes Receivable Total investments Tot

Slide 37: Conclusion
PDL Conclusion

Slide 38: Investment Highlights and Priorities
ent Highlights and Priorities Tekturna and Rasilez are important products for treatment of hypertension with aj differentiated mechanism of action and potential upside in revenues if promoted} appropriately. Noden investment was immediately cash flow accretive to PDL. We have a team with demonstrate
Source: SEC EDGAR · 8-K filed Apr 10, 2018
More decks from PDL BioPharma Inc
Q3 2020 Earnings Presentation13 slides · Nov 13, 2020
Investor Presentation (September 2020)32 slides · Sep 10, 2020
Q2 2020 Earnings Presentation17 slides · Aug 6, 2020
Investor Presentation (July 2020)30 slides · Jul 17, 2020
Q1 2020 Earnings Presentation15 slides · May 7, 2020
Q4 2019 Earnings Presentation16 slides · Mar 11, 2020